STING1 and neoplasm: This study provided a proof-of-concept that intravenous injection of SR717@RGE-HFn NPs effectively activates the STING pathway and exerts immunoregulatory effects within the intracranial glioma TME, leading to the inhibition of tumor progression with excellent biocompatibility.